Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Inclusion criteria

• ✓. Women ≥18 years old
• ✓. Histologically or cytologically confirmed locally advanced or metastatic breast cancer.
• ✓. Pathologically documented breast cancer that is HER2-negative for both primary tumor and metastases (if puncture results are available)
• ✓. ECOG PS of 0-1.
• ✓. For locally advanced or metastatic breast cancer, the tumor tissue HRD score\> 42 is needed (for HRD testing, the recipient must provide a test report from an institution with a qualified testing unit prior to enrollment; if no report is available, the relevant test sample must be provided for confirmation in the central laboratory prior to enrollment).
• ✓. Presence of at least 1 measurable lesion based on computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1).
• ✓. If treated with PARP inhibitors or immune checkpoint inhibitors in the (neo) adjuvant phase, a relapse-free interval of more than 1 year after the end of treatment is required.
• ✓. Prior treatment with paclitaxel-based chemotherapeutic agents is allowed.

Exclusion criteria